Cargando…
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer
INTRODUCTION: Targeted multimodal approaches need to be strategically developed to control tumour growth and prevent metastatic burden successfully. Breast cancer presents a unique clinical problem because of the variety of cellular subtypes that arise. The tumour stage and cellular subtypes often d...
Autores principales: | Sambi, Manpreet, Samuel, Vanessa, Qorri, Bessi, Haq, Sabah, Burov, Sergey V, Markvicheva, Elena, Harless, William, Szewczuk, Myron R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260544/ https://www.ncbi.nlm.nih.gov/pubmed/32546966 http://dx.doi.org/10.2147/DDDT.S242514 |
Ejemplares similares
-
Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
por: Qorri, Bessi, et al.
Publicado: (2022) -
Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity
por: Sambi, Manpreet, et al.
Publicado: (2017) -
Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression
por: Qorri, Bessi, et al.
Publicado: (2022) -
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells
por: Qorri, Bessi, et al.
Publicado: (2020) -
Functionalized Folic Acid-Conjugated Amphiphilic Alternating Copolymer Actively Targets 3D Multicellular Tumour Spheroids and Delivers the Hydrophobic Drug to the Inner Core
por: Li, Xia, et al.
Publicado: (2018)